HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Datseris, I. E. Articles by Britton, K. E. Search for Related Content PubMed PubMed Citation Articles by Datseris, I. E. Articles by Britton, K. E.

Captopril Renal Scintigraphy in Patients with Hypertension and Chronic Renal Failure

Department of Nuclear Medicine, St. Bartholomew's Hospital
Department of Nuclear Medicine and Nephrology, Charing Cross Hospital, London, England

Correspondence: For correspondence or reprints contact: Dr. J. Bomanji, Dept. of Nuclear Medicine, St. Bartholomew's Hospital, West Smithfield, London EC1A 7BE, U.K.

ABSTRACT

The aim of this prospective study was to determine the ability of the captopril renogram to reveal the presence of angiotensin II-dependent renovascular disorder in hypertensive patients with chronic renal failure and to assess the possibility of predicting beneficial effect of angiotensin-converting enzyme (ACE) inhibitors on renal function. Methods: Forty-one patients were evaluated. Baseline renal scintigraphy was performed with 80 MBq of ^99mTc-mercaptoacetylthriglycine (MAG3) injected intravenously. Scintigraphy was repeated within a week with 25 mg of oral captopril given 60 min prior to the test. Using the measurements outlined by the Working Party on Diagnostic Criteria of Renovascular Hypertension with Captopril Renography, the patients were categorized into high (7 patients), indeterminate (19 patients) and low (15 patients) probability for renal artery stenosis (RAS). Results: In five of the seven patients with high probability, the presence of RAS was confirmed angiographically and corrective surgical procedure performed in two. In patients with GFR of 10 ml/min/1.73 m² and/or split renal function of 10% or less, all qualitative and semiquantitative scintigraphic parameters were nonspecific. Mean parenchymal transit time of tracer was a useful parameter to predict the beneficial effect of ACE inhibition therapy in 23 patients (14 low and 9 indeterminate probability of RAS). Conclusion: In hypertensive patients with renal failure, captopril renal scintigraphy can be utilized to identify the presence of angiotensin II-dependent renal dysfunction and possibly help to predict the beneficial effect of ACE inhibitor therapy.

Key Words: renal scintigraphy • captopril renal scintigraphy • hypertension • chronic renal failure

This article has been cited by other articles:

				R G Woolfson Renal failure in atherosclerotic renovascular disease: pathogenesis, diagnosis, and intervention Postgrad. Med. J., February 1, 2001; 77(904): 68 - 74. [Full Text]

				E. J. Fine, Y. Li, and M. D. Blaufox Parenchymal Mean Transit Time Analysis of 99mTc-DTPA Captopril Renography J. Nucl. Med., October 1, 2000; 41(10): 1627 - 1631. [Abstract] [Full Text] [PDF]